RT Journal Article
SR Electronic
T1 Cohort Profile: the Oxford Parkinson’s Disease Centre Discovery Cohort Magnetic Resonance Imaging sub-study (OPDC-MRI)
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 19005819
DO 10.1101/19005819
A1 Ludovica Griffanti
A1 Johannes C Klein
A1 Konrad Szewczyk-Krolikowski
A1 Ricarda A L Menke
A1 Michal Rolinski
A1 Thomas R Barber
A1 Michael Lawton
A1 Samuel G Evetts
A1 Faye Begeti
A1 Marie Crabbe
A1 Jane Rumbold
A1 Richard Wade-Martins
A1 Michele T. Hu
A1 Clare E Mackay
YR 2019
UL http://medrxiv.org/content/early/2019/09/11/19005819.abstract
AB Purpose The Oxford Parkinson’s Disease Centre (OPDC) Discovery Cohort magnetic resonance imaging (MRI) sub-study (OPDC-MRI) collects high quality multimodal brain MRI together with deep longitudinal clinical phenotyping in patients with Parkinson’s, at-risk individuals and healthy elderly participants. The primary aim is to detect pathological changes in brain structure and function, and develop, together with the clinical data, biomarkers to stratify, predict and chart progression in early-stage Parkinson’s and at-risk individuals.Participants Participants are recruited from the OPDC Discovery Cohort, a prospective, longitudinal study. Baseline MRI data is currently available for 290 participants: 119 patients with early idiopathic Parkinson’s, 15 Parkinson’s patients with pathogenic mutations of the LRRK2 or GBA genes, 68 healthy controls and 87 individuals at risk of Parkinson’s (asymptomatic carriers of GBA mutation and patients with idiopathic rapid eye movement sleep behaviour disorder - RBD).Findings to date Differences in brain structure in early Parkinson’s were found to be subtle, with small changes in the shape of the globus pallidus and evidence of alterations in microstructural integrity in the prefrontal cortex that correlated with performance on executive function tests. Brain function, as assayed with resting fMRI yielded more substantial differences, with basal ganglia connectivity reduced in early Parkinson’s, and RBD, but not Alzheimer’s, suggesting that the effect is pathology specific. Imaging of the substantia nigra with the more recent adoption of sequences sensitive to iron and neuromelanin content shows promising results in identifying early signs of Parkinsonian disease.Future plans Ongoing studies include the integration of multimodal MRI measures to improve discrimination power. Follow-up clinical data are now accumulating and will allow us to correlate baseline imaging measures to clinical disease progression. Follow-up MRI scanning started in 2015 and is currently ongoing, providing the opportunity for future longitudinal imaging analyses with parallel clinical phenotyping.Strengths and limitations of this studyHigh quality 3T MRI data in a very well phenotyped and longitudinally followed cohort of Parkinson’s and RBD.All imaging data were acquired on the same MRI scanner, quite unique for a study of this duration. The protocol includes both standard sequences, comparable across other studies, and sequences acquired to investigate study-specific research questions.Clinical longitudinal data are acquired every 18 months and will be used to relate baseline imaging with clinical progression. Information about conversion to Parkinson’s of the at-risk individuals will also be available, providing the ultimate validation of potential biomarkers. MRI follow-up is also ongoing, which will allow longitudinal imaging analyses.Statistical maps of published results and support data relative to the analyses are available to share.OPDC-MRI phenotyping is deep and relatively frequent, however the size of the cohort is not at the level of population-level cohort studies. MRI sequences are high quality, but could not exploit the latest advances in the field in order to maintain continuity.Competing Interest StatementMTH reports grants from Parkinson's UK Monument Discovery Award during the conduct of the study; other from Biogen Digital and Roche Prodromal Advisory Boards, outside the submitted work. Other authors have nothing to declare.Funding StatementThe work was supported by the Monument Trust Discovery Award from Parkinson’s UK (J-1403) and by the Wellcome Centre for Integrative Neuroimaging, the MRC Dementias Platform UK, the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC), and the NIHR Oxford Health BRC (a partnership between Oxford Health NHS Foundation Trust and the University of Oxford). The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. JCK acknowledges support from the NIHR Oxford Health Clinical Research Facility. MR received funding support from a NIHR Academic Clinical Lectureship and a NIHR Oxford BRC Doctoral Training Fellowship. TRB received funding support from a Wellcome Trust Doctoral Training Fellowship, and a Biomedical Research Council Career Development Fellowship. FB reports personal fundings from National Institute for Health Research, during the conduct of the study.Author DeclarationsAll relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesAny clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.Not ApplicableI have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.YesThe data presented in this work will be available through the Dementias Platform UK, where data can be accessed by submitting a study proposal. Statistical maps are available on NeuroVault.org (links in manuscript) and support data related to the analyses are available on ORA Data. https://portal.dementiasplatform.uk https://ora.ox.ac.uk/objects/uuid:8200af66-f438-4a7b-ad14-e8b032f0a9e7